LIQUIDIA TECH
PharmaLIQUIDIA TECH is a pharmaceutical company focused on Cardiovascular, Respiratory. Key products include YUTREPIA.
LIQUIDIA TECH at a Glance
- Fast trial execution (14 months median completion)
LIQUIDIA TECH's Key Drugs
LIQUIDIA TECH's core commercial portfolio centers on YUTREPIA, spanning Cardiovascular and Respiratory — its most strategically important drugs approved in the last 15 years.
LIQUIDIA TECH's Recent FDA Approvals
LIQUIDIA TECH secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
LIQUIDIA TECH's Therapeutic Areas
LIQUIDIA TECH's approved drugs and pipeline span 2 therapeutic areas, led by Cardiovascular and Respiratory, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
LIQUIDIA TECH's Top Competitors
LIQUIDIA TECH's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and Bayer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
LIQUIDIA TECH Pipeline Snapshot
LIQUIDIA TECH has 10 active clinical programs from ClinicalTrials.gov — 8 Phase 3, 2 Phase 2 and 0 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • YUTREPIA leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 1/4 completed
- • Speed: 14 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2025-05-23
- Latest
- 2025-05-23
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges